Eli Lilly's GLP-1 Franchise to Drive 26% Revenue Growth in 2026, BofA Securities Says

MT Newswires Live12-16

Eli Lilly's (LLY) GLP-1 franchise for weight loss is set to drive 26% revenue growth in 2026, BofA Securities said in a Monday note.

The company expects to launch orfoglipron in Q2 2026 and could lead to a "meaningful" category expansion, the investment firm said. Orfoglipron should launch well and could generate $3 billion in revenue in the first year, BofA noted.

Meanwhile, Mounjaro is expected to remain Eli Lilly's "top selling brand for the foreseeable future," for diabetes in the US and for both obesity and diabetes outside the US, the investment firm said.

In addition, Eli Lilly's recent US government deal is expected to spur uptake of the company's obesity medications starting in Q2 2026, BofA said.

BofA lowered its price target on Eli Lilly to $1,268 from $1,286, while maintaining its buy rating.

Price: 1059.05, Change: +31.54, Percent Change: +3.07

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2591262804?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-16 00:35","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2591262804","market":"us","top_or_hot":-1,"title":"Eli Lilly's GLP-1 Franchise to Drive 26% Revenue Growth in 2026, BofA Securities Says","media":"MT Newswires Live","content":"<html><body><p> Eli Lilly's (LLY) GLP-1 franchise for weight loss is set to drive 26% revenue growth in 2026, BofA Securities said in a Monday note.</p><p>The company expects to launch orfoglipron in Q2 2026 and could lead to a \"meaningful\" category expansion, the investment firm said. Orfoglipron should launch well and could generate $3 billion in revenue in the first year, BofA noted.</p><p>Meanwhile, Mounjaro is expected to remain Eli Lilly's \"top selling brand for the foreseeable future,\" for diabetes in the US and for both obesity and diabetes outside the US, the investment firm said.</p><p>In addition, Eli Lilly's recent US government deal is expected to spur uptake of the company's obesity medications starting in Q2 2026, BofA said.</p><p>BofA lowered its price target on Eli Lilly to $1,268 from $1,286, while maintaining its buy rating.</p><p>Price: 1059.05, Change: +31.54, Percent Change: +3.07</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Eli Lilly's GLP-1 Franchise to Drive 26% Revenue Growth in 2026, BofA Securities Says</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nEli Lilly's GLP-1 Franchise to Drive 26% Revenue Growth in 2026, BofA Securities Says\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-12-16 00:35</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Eli Lilly's (LLY) GLP-1 franchise for weight loss is set to drive 26% revenue growth in 2026, BofA Securities said in a Monday note.</p><p>The company expects to launch orfoglipron in Q2 2026 and could lead to a \"meaningful\" category expansion, the investment firm said. Orfoglipron should launch well and could generate $3 billion in revenue in the first year, BofA noted.</p><p>Meanwhile, Mounjaro is expected to remain Eli Lilly's \"top selling brand for the foreseeable future,\" for diabetes in the US and for both obesity and diabetes outside the US, the investment firm said.</p><p>In addition, Eli Lilly's recent US government deal is expected to spur uptake of the company's obesity medications starting in Q2 2026, BofA said.</p><p>BofA lowered its price target on Eli Lilly to $1,268 from $1,286, while maintaining its buy rating.</p><p>Price: 1059.05, Change: +31.54, Percent Change: +3.07</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LLY","symbol_name":"礼来","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2591262804","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2591262804","pubTimestamp":1765816526,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Eli Lilly's  GLP-1 franchise for weight loss is set to drive 26% revenue growth in 2026, BofA Securities said in a Monday note.The company expects to launch orfoglipron in Q2 2026 and could lead to a \"meaningful\" category expansion, the investment firm said. Orfoglipron should launch well and could generate $3 billion in revenue in the first year, BofA noted.Meanwhile, Mounjaro is expected to remain Eli Lilly's \"top selling brand for the foreseeable future,\" for diabetes in the US and for both obesity and diabetes outside the US, the investment firm said.In addition, Eli Lilly's recent US government deal is expected to spur uptake of the company's obesity medications starting in Q2 2026, BofA said.BofA lowered its price target on Eli Lilly to $1,268 from $1,286, while maintaining its buy rating.Price: 1059.05, Change: +31.54, Percent Change: +3.07","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"LLY":"礼来","GLP":"Global Partners Lp"},"translate_title":"美银证券表示，礼来公司的GLP-1特许经营权将推动2026年收入增长26%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LLY":1.5,"GLP":1.5},"content_text":"Eli Lilly's (LLY) GLP-1 franchise for weight loss is set to drive 26% revenue growth in 2026, BofA Securities said in a Monday note.The company expects to launch orfoglipron in Q2 2026 and could lead to a \"meaningful\" category expansion, the investment firm said. Orfoglipron should launch well and could generate $3 billion in revenue in the first year, BofA noted.Meanwhile, Mounjaro is expected to remain Eli Lilly's \"top selling brand for the foreseeable future,\" for diabetes in the US and for both obesity and diabetes outside the US, the investment firm said.In addition, Eli Lilly's recent US government deal is expected to spur uptake of the company's obesity medications starting in Q2 2026, BofA said.BofA lowered its price target on Eli Lilly to $1,268 from $1,286, while maintaining its buy rating.Price: 1059.05, Change: +31.54, Percent Change: +3.07","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2591262804","isCrawlerRequest":true}